<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506882</url>
  </required_header>
  <id_info>
    <org_study_id>N01375</org_study_id>
    <nct_id>NCT01506882</nct_id>
  </id_info>
  <brief_title>An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy</brief_title>
  <official_title>An Open-label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Levetiracetam Used as Monotherapy in Newly or Recently Diagnosed Epilepsy Patients Aged Older Than or Equal to 16 Years With Partial Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Japan Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Levetiracetam (LEV) used as
      monotherapy, with efficacy measured as 6-month seizure freedom at the last evaluated dose in
      the LEV 1000 mg/day to 2000 mg/day group, in newly or recently diagnosed Epilepsy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period</measure>
    <time_frame>From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period</time_frame>
    <safety_issue>No</safety_issue>
    <description>A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free:
A documented seizure during 6 consecutive months of the Evaluation Analysis Period
Subject discontinued the study prematurely during the Evaluation Analysis Period
Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period</measure>
    <time_frame>From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving the same dose of LEV as in the Evaluation Period during the 26-weeks Maintenance Period unless a seizure occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period</measure>
    <time_frame>From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period</time_frame>
    <safety_issue>No</safety_issue>
    <description>A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free:
A documented seizure during 6 consecutive months of the Evaluation Analysis Period
Subject discontinued the study prematurely during the Evaluation Analysis Period
Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period</measure>
    <time_frame>From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving LEV 3000 mg/day during the 26-weeks Maintenance Period unless a seizure occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Seizure at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group</measure>
    <time_frame>During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered.
The Median time to first seizure will be estimated from the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Withdrawal at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group</measure>
    <time_frame>During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Median time to withdrawal will be estimated from the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Seizure in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group</measure>
    <time_frame>During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered.
The Median time to first seizure will be estimated from the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group</measure>
    <time_frame>During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Median time to withdrawal will be estimated from the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Epilepsy</condition>
  <condition>Partial Onset Seizures</condition>
  <arm_group>
    <arm_group_label>Levetiracetam 1000 mg/day to 2000 mg/day group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1-week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day.
The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levetiracetam 3000 mg/day group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks.
Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period. They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period.
The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam (LEV)</intervention_name>
    <description>Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: First study dose is 1000 mg/day and if a seizure occurs, the dose will be increased to 2000 mg/day. Max dose in the Follow Up Period is 3000 mg/day.
Frequency: Twice daily</description>
    <arm_group_label>Levetiracetam 1000 mg/day to 2000 mg/day group</arm_group_label>
    <other_name>Keppra, E Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam (LEV)</intervention_name>
    <description>Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: 1000 mg/day for first two weeks, then 2000 mg/day for two weeks then 3000 mg/day by the end of the trial.
Frequency: Twice daily</description>
    <arm_group_label>Levetiracetam 3000 mg/day group</arm_group_label>
    <other_name>Keppra, E Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female and aged â‰¥ 16 years at Visit 1

          -  Subjects with newly or recently diagnosed Epilepsy having experienced unprovoked
             Partial Seizures (IA, IB, IC), that are classifiable according to the International
             League Against Epilepsy (ILAE) classification of Epileptic Seizures

          -  Subjects with at least 2 unprovoked seizures separated by a minimum of 48 hours in
             the year prior to Visit 1, of which, at least 1 unprovoked seizure occurred in the 3
             months prior to Visit 1

          -  Minimum body weight of 40 kg at Visit 1

        Exclusion Criteria:

          -  Subject has a history or presence of seizure types other than partial (IA, IB, IC)

          -  Subject has an experience of any type of brain surgery in the consecutive 2 years
             prior to Visit 1

          -  Subject has a history or presence of known Pseudo-Seizures

          -  Subject has been treated for Epilepsy with any Antiepileptic Drug (AED) within the 6
             months prior to Visit 1. However, acute and sub-acute seizure treatments are accepted
             for a maximum use of 2 weeks, if the treatments are stopped for the week prior to
             Visit 1

          -  Subject has a known clinically significant acute or chronic illness, such as but not
             restricted to: cardiac, renal, hepatic dysfunction, endocrinological, or psychiatric
             illness, and that may impair reliable participation in the study or necessitate the
             use of medication not allowed by the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>19</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>33</name>
      <address>
        <city>Asaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>21</name>
      <address>
        <city>Daito</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>12</name>
      <address>
        <city>Fujisawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>14</name>
      <address>
        <city>Hamamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>11</name>
      <address>
        <city>Himeji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>30</name>
      <address>
        <city>Hirosaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>8</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>20</name>
      <address>
        <city>Kamakura</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>17</name>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3</name>
      <address>
        <city>Kitakyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>26</name>
      <address>
        <city>Kodaira</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9</name>
      <address>
        <city>Kokubunji</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>32</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>25</name>
      <address>
        <city>Miyakonojo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5</name>
      <address>
        <city>Nagoya Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>22</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>24</name>
      <address>
        <city>Osakasayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>15</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>27</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>13</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1</name>
      <address>
        <city>Sakai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>29</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2</name>
      <address>
        <city>Toyonaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>7</name>
      <address>
        <city>Ube</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.keppraxr.com/includes/pdf/Keppra_IR_Current_30E.pdf</url>
    <description>Product Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 4, 2015</lastchanged_date>
  <firstreceived_date>January 5, 2012</firstreceived_date>
  <firstreceived_results_date>October 7, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levetiracetam</keyword>
  <keyword>Monotherapy</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Partial Onset Seizures</keyword>
  <keyword>Japan</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This multicenter study started to enroll subjects in December 2011 in order to end up with 27 centers with enrolled subjects in Japan.
Participant Flow refers to the Randomized Set (RS). RS consists of all subjects who were randomized to the study groups.</recruitment_details>
      <pre_assignment_details>Data provided here are Interim Results. The cutoff date for the first interim analysis was 17-Oct-2013.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Levetiracetam 1000 mg/Day to 2000 mg/Day Group</title>
          <description>Levetiracetam (LEV): Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: First study dose is 1000 mg/day and if a seizure occurs, the dose will be increased to 2000 mg/day. Max dose in the Follow Up Period is 3000 mg/day.
Frequency: Twice daily</description>
        </group>
        <group group_id="P2">
          <title>Levetiracetam 3000 mg/Day Group</title>
          <description>Levetiracetam (LEV): Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: 1000 mg/day for first two weeks, then 2000 mg/day for two weeks then 3000 mg/day by the end of the trial.
Frequency: Twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 Evaluation and Connected Periods</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2 Maintenance and Connected Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44">Since Mainten. Period could be skipped, there could be less subjects in Part 2 than completed Part 1</participants>
                <participants group_id="P2" count="2">Since Mainten. Period could be skipped, there could be less subjects in Part 2 than completed Part 1</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Still Ongoing at 1st interim cut-off</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Safety Set (SS). SS consists of all subjects in the Enrolled Set, who received at least 1 dose of the Investigational Medicinal Product (IMP).</population>
      <group_list>
        <group group_id="B1">
          <title>Levetiracetam 1000 mg/Day to 2000 mg/Day Group</title>
          <description>Levetiracetam (LEV): Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: First study dose is 1000 mg/day and if a seizure occurs, the dose will be increased to 2000 mg/day. Max dose in the Follow Up Period is 3000 mg/day.
Frequency: Twice daily</description>
        </group>
        <group group_id="B2">
          <title>Levetiracetam 3000 mg/Day Group</title>
          <description>Levetiracetam (LEV): Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: 1000 mg/day for first two weeks, then 2000 mg/day for two weeks then 3000 mg/day by the end of the trial.
Frequency: Twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="71"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36.5" spread="18.0"/>
                <measurement group_id="B2" value="37.0" spread="18.6"/>
                <measurement group_id="B3" value="36.5" spread="17.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="53"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="38"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Japan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="61"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="71"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="58.98" spread="12.30"/>
                <measurement group_id="B2" value="62.58" spread="15.11"/>
                <measurement group_id="B3" value="59.48" spread="12.67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="161.96" spread="8.77"/>
                <measurement group_id="B2" value="166.07" spread="10.21"/>
                <measurement group_id="B3" value="162.54" spread="9.02"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period</title>
        <description>A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free:
A documented seizure during 6 consecutive months of the Evaluation Analysis Period
Subject discontinued the study prematurely during the Evaluation Analysis Period
Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.</description>
        <time_frame>From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data for the primary outcome measure refer to the Full Analysis Set (FAS). FAS includes all subjects in the Safety Set who had at least 1 treatment day in the Evaluation Period. This means that subjects in LEV 1000 to 2000 mg/day group had to have at least 1 treatment day in the Evaluation Period on their final evaluated dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam 1000 mg/Day to 2000 mg/Day Group</title>
            <description>Levetiracetam (LEV): Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: First study dose is 1000 mg/day and if a seizure occurs, the dose will be increased to 2000 mg/day. Max dose in the Follow Up Period is 3000 mg/day.
Frequency: Twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period</title>
            <description>A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free:
A documented seizure during 6 consecutive months of the Evaluation Analysis Period
Subject discontinued the study prematurely during the Evaluation Analysis Period
Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="73.8" lower_limit="60.9" upper_limit="84.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy variable was to be calculated as the proportion p=n/N of subjects (n) staying seizure free for 6 months out of the total number of subjects (N). For this proportion p, an exact 2-sided 95% confidence interval (CI) was computed based on the F distribution.
The hypothesis H0: p=0.4 was to be formally rejected in favor of H1: p&gt;0.4, if the lower confidence limit for p was greater than 0.4.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Percent</param_type>
            <param_value>73.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>60.9</ci_lower_limit>
            <ci_upper_limit>84.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period</title>
        <description>Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving the same dose of LEV as in the Evaluation Period during the 26-weeks Maintenance Period unless a seizure occurs.</description>
        <time_frame>From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>06/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period</title>
        <description>A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free:
A documented seizure during 6 consecutive months of the Evaluation Analysis Period
Subject discontinued the study prematurely during the Evaluation Analysis Period
Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.</description>
        <time_frame>From the end of the 1-week Stabilization Period over the 26-weeks Evaluation Period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data for this secondary outcome measure refer to the Full Analysis Set (FAS). FAS includes all subjects in the Safety Set who had at least 1 treatment day in the Evaluation Period. This means that subjects in LEV 1000 to 2000 mg/day group had to have at least 1 treatment day in the Evaluation Period on their final evaluated dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam 3000 mg/Day Group</title>
            <description>Levetiracetam (LEV): Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: 1000 mg/day for first two weeks, then 2000 mg/day for two weeks then 3000 mg/day by the end of the trial.
Frequency: Twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period</title>
            <description>A subject was considered seizure free, if no seizure occurred during the 6 consecutive months (26 weeks) in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free:
A documented seizure during 6 consecutive months of the Evaluation Analysis Period
Subject discontinued the study prematurely during the Evaluation Analysis Period
Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22.2" lower_limit="2.8" upper_limit="60.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects in the Levetiracetam (LEV) 3000 mg/Day Group Who Are Seizure Free for 52 Consecutive Weeks of Treatment During the Evaluation Period and the Maintenance Period</title>
        <description>Subjects who complete the 26-weeks Evaluation Period without having a seizure will continue receiving LEV 3000 mg/day during the 26-weeks Maintenance Period unless a seizure occurs.</description>
        <time_frame>From entry in the 26-weeks Evaluation Period to the end of the 26-weeks Maintenance Period</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>06/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Seizure at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group</title>
        <description>Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered.
The Median time to first seizure will be estimated from the Kaplan-Meier curve.</description>
        <time_frame>During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>06/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Withdrawal at the Last Evaluated Dose in Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group</title>
        <description>Median time to withdrawal will be estimated from the Kaplan-Meier curve.</description>
        <time_frame>During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>06/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Seizure in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group</title>
        <description>Time was measured from first day of last evaluated dose. Seizures during Stabilization were not considered.
The Median time to first seizure will be estimated from the Kaplan-Meier curve.</description>
        <time_frame>During Evaluation, Maintenance and Safety Follow Up Period after 1-week Stabilization Period, assessed up to 1 year</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>06/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group</title>
        <description>Median time to withdrawal will be estimated from the Kaplan-Meier curve.</description>
        <time_frame>During 1-week Stabilization Period, Evaluation, Maintenance and Safety Follow Up Period, assessed up to 1 year</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data for this secondary outcome measure refer to the Full Analysis Set (FAS). FAS includes all subjects in the Safety Set who had at least 1 treatment day in the Evaluation Period.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam 3000 mg/Day Group</title>
            <description>Levetiracetam (LEV): Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: 1000 mg/day for first two weeks, then 2000 mg/day for two weeks then 3000 mg/day by the end of the trial.
Frequency: Twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Withdrawal in Subjects in the Levetiracetam (LEV) 3000 mg/Day Group</title>
            <description>Median time to withdrawal will be estimated from the Kaplan-Meier curve.</description>
            <units>days</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="91" lower_limit="21" upper_limit="197"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events presented here, were collected during Part 1 (Up-Titration + Stabilization 1 + Evaluation 1 + Stabilization 2 + Evaluation 2 + Withdrawal Period) until Database Lock for the 1st Interim Analysis on 17-Oct-2013.</time_frame>
      <desc>Adverse Events refer to the Safety Set including all subjects in the Enrolled Set who received at least 1 dose of the Investigational Medicinal Product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Levetiracetam 1000 mg/Day to 2000 mg/Day Group</title>
          <description>Levetiracetam (LEV): Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: First study dose is 1000 mg/day and if a seizure occurs, the dose will be increased to 2000 mg/day. Max dose in the Follow Up Period is 3000 mg/day.
Frequency: Twice daily</description>
        </group>
        <group group_id="E2">
          <title>Levetiracetam 3000 mg/Day Group</title>
          <description>Levetiracetam (LEV): Formulation: Tablet
Strength: LEV 250 mg, LEV 500 mg
Dosage: 1000 mg/day for first two weeks, then 2000 mg/day for two weeks then 3000 mg/day by the end of the trial.
Frequency: Twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Kaposi's varicelliform eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Meniscus removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="43" subjects_affected="31" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB Clinical Trial Call Center</name_or_title>
      <organization>UCB</organization>
      <phone>+1 877 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
